ASCO Guidelines

180 Folgen

1. Adjuvant Therapy for Stage II Colon Cancer Guideline Update

   Vom: 22.12.2021
2. Management of Stage III NSCLC Guideline

   Vom: 22.12.2021
3. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

   Vom: 21.12.2021
4. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline

   Vom: 13.12.2021
5. Abemaciclib with Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update

   Vom: 10.12.2021
6. Considerations for the Use of Steroids: Management of irAEs Guideline (Part 13)

   Vom: 16.11.2021
7. Ocular Toxicities: Management of irAEs Guideline (Part 12)

   Vom: 15.11.2021
8. Cardiovascular Toxicities: Management of irAEs Guideline (Part 11)

   Vom: 12.11.2021
9. Hematologic Toxicities: Management of irAEs Guideline (Part 10)

   Vom: 11.11.2021
10. Nervous System Toxicities: Management of irAEs Guideline (Part 9)

    Vom: 10.11.2021
11. Renal Toxicities: Management of irAEs Guideline (Part 8)

    Vom: 9.11.2021
12. Musculoskeletal Toxicities: Management of irAEs Guideline (Part 7)

    Vom: 8.11.2021
13. Endocrine Toxicities: Management of irAEs Guideline (Part 6)

    Vom: 5.11.2021
14. Lung Toxicities: Management of irAEs Guideline (Part 5)

    Vom: 4.11.2021
15. Gastrointestinal Toxicities: Management of irAEs Guideline (Part 4)

    Vom: 3.11.2021
16. Cutaneous Toxicities: Management of irAEs Guideline (Part 3)

    Vom: 2.11.2021
17. ICPi Overview: Management of irAEs Guideline (Part 1)

    Vom: 1.11.2021
18. CAR-T Cell Therapy: Management of irAEs Guideline (Part 2)

    Vom: 1.11.2021
19. Immunotherapy in Patients with Locally Advanced Esophageal Carcinoma: ASCO Guideline Rapid Recommendation Update

    Vom: 18.8.2021
20. Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update

    Vom: 3.8.2021